AMAG Pharma (AMAG) Submits NDA to FDA for Bremelanotide for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
Tweet Send to a Friend
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
